The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE., J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8., 2011 Jan 01

Abstract

This purpose of this paper is to investigate the impact of Paragraph IV patent infringement decisions on brand drug pharmaceutical firms. Paragraph IV decisions determine whether a generic firm can enter before the period of exclusivity ends.

I construct a novel dataset of all Paragraph IV decisions and find that they disproportionately involve the highest revenue drugs, significant periods of patent protection, and a non-trivial portion of all brand drugs facing generic entry.

I also estimate the impact of Paragraph IV decisions on brand firm profitability and find they have large value consequences.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

Related Publications

Personalized hypertension management using patient-generated health data integrated with electronic health records (EMPOWER-H): six-month pre-post study.

Lv N, Xiao L, Simmons ML, Rosas LG, Chan A, Entwistle M.
J Med Internet Res. 19(9):e311. doi: 10.2196/jmir.7831.
2017 Sep 19

A framework for examining the function of digital health technologies for weight management.

Azar KMJ, Bennett GG, Nolting LA, Rosas LG, Burke LE, Ma J.
Transl Behav Med. doi: 10.1093/tbm/ibx050. [Epub ahead of print]
2018 Jan 27

Implementation of patient-reported outcomes measurement information system data collection in a private orthopedic surgery practice.

Haskell A, Kim T.
Foot Ankle Int. 1071100717753967. doi: 10.1177/1071100717753967. [Epub ahead of print]
2018 Jan 01

Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment.

Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, Anderson H, Boscarino JA, Schmidt MA, Daida YG, Sahota A, Vincent J, Bowlus CL, Lindor K, Zhang T, Trudeau S, Li J, Rupp LB, Gordon SC; FOLD Investigators.
Clin Gastroenterol Hepatol. pii: S1542-3565(17)31529-X. doi: 10.1016/j.cgh.2017.12.033. [Epub ahead of print]
2017 Dec 22

Patient experiences in selecting a Medicare Part D prescription drug plan.

Stults CD, Baskin AS, Bundorf MK, Tai-Seale M.
J Patient Experience. https://doi.org/10.1177/2374373517739413
2017 Nov 21

We've expanded your view

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Abstract

Pubmed Abstract

Associated Topics

Related Publications

Personalized hypertension management using patient-generated health data integrated with electronic health records (EMPOWER-H): six-month pre-post study.

A framework for examining the function of digital health technologies for weight management.

Implementation of patient-reported outcomes measurement information system data collection in a private orthopedic surgery practice.

Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment.

Patient experiences in selecting a Medicare Part D prescription drug plan.

About Sutter

Find Care

Featured Services

Patient Resources

Our Team